论文部分内容阅读
目的研究用表面增强拉曼光谱法追踪马来酸依那普利片的体内消除过程,并对其安全用药提出建议。方法分别采集15例患者的尿液与粪便,通过前处理后与表面信号增强药等体积混合,以(1470±2)/cm依那普利特征峰强度进行检测,计算病人体内消除部分的主药浓度,作出相关分析。结果方法回收率高,相对标准偏差在3%以内,尿样中主药浓度在5~100μg·m L~(-1)呈良好线性关系,最低检测限为0.5μg·m L~(-1);粪样中主药浓度在1~50μg·m L~(-1)呈良好线性关系,最低检测限为1.3μg·m L~(-1)。11例患者(共纳入15例)显效,4例显效不明显。结论本研究方法简便迅速,可以用于血管紧张素Ⅰ转化酶抑制药的体内代谢分析与临床评价。
Objective To investigate the in vivo elimination of enalapril maleate by surface enhanced Raman spectroscopy and to provide recommendations for its safe use. Methods Urine and faeces were collected from 15 patients. After pretreatment, the volume of enalapril (1470 ± 2) / cm peak intensity was detected by volume mixing of pretreatment with surface signal enhancing drug. The main drug concentration, make relevant analysis. Results The recovery rate was high and the relative standard deviation was less than 3%. The main drug concentration in urine samples showed a good linearity in the range of 5-100 μg · m L -1 with the detection limit of 0.5 μg · m L -1 ). The concentration of the main drug in the feces sample showed a good linear relationship with the concentration of 1 ~ 50μg · m L -1 with the detection limit of 1.3μg · m L -1. Eleven patients (15 were enrolled in total) were significantly effective, 4 markedly notable. Conclusion The method is simple and rapid and can be used for in vivo metabolic analysis and clinical evaluation of angiotensin I converting enzyme inhibitors.